ProCE Banner Activity

NADIA: Wk 96 Results With DTG vs DRV/RTV and TDF vs ZDV as Second-line ART in Africa

Slideset Download
Conference Coverage
This trial supports use of DTG + 2 NRTIs as second-line ART, even if NRTIs are predicted to have no activity, but resistance is a concern.

Released: February 18, 2022

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare